Matthieu Allez

Université Paris-Saclay

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

LINKED CONTENT This article is linked to Carbonnel et al paper. To view this article, visit https://doi.org/10.1111/apt.17352

Year:

2023

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Laurent Peyrin‐Biroulet

FRANCE

View details

Guillaume Savoye

professor

University of Rouen

FRANCE

View details

Anna Fogdell-Hahn

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Matthieu Allez

Research Interests

Explore related searches

Contact this professor

Articles (11)

Editorial: severe colitis induced by targeted therapies in dermato‐oncology beyond check point‐inhibitors

A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort

Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach

Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine.

Care of the Patient with IBD Requiring Hospitalization During the COVID-19 Pandemic.

Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease.

KLRG1 and CD103 Expressions Define Distinct Intestinal Tissue-Resident Memory CD8 T Cell Subsets Modulated in Crohn's Disease.

Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting.

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease

Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease

Collaborators (3)

Laurent Peyrin‐Biroulet

Guillaume Savoye

Anna Fogdell-Hahn

Make your next move.